Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyPremera Bluecross IEI testing Coverage Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedPremera BluecrossPolicy G2056

    Diagnosis of Idiopathic Environmental Intolerance (IEI) testing

    Customize your policy alerts

    Sign up for Premera Bluecross Policy G2056 alerts

    Get alerted when Policy G2056 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement for laboratory and diagnostic testing proposed to diagnose or screen for idiopathic environmental intolerance (IEI) and related proprietary panels; it applies to Premera Blue Cross benefit determinations and providers ordering such tests.

    Policy Summary
    PayerPremera Bluecross
    PolicyDiagnosis of Idiopathic Environmental Intolerance (IEI) testing
    Policy CodePolicy G2056
    Change TypeAdded non-reimbursable statementcoding removal
    Effective DateFeb 6, 2026
    Last ReviewFeb 6, 2026
    Next Review Date
    Key ActionDo not order tests intended to diagnose IEI — claims for any IEI testing will not be reimbursed.
    SourceLink
    POLICY UPDATE CHANGES

    In all circumstances, any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable.

    Removed CPT codes 83921 and 84600 from coding.

    All circumstancesIEI tests not reimbursable
    91065Breath H2/CH4 tests impacted
    2CPT codes removed
    NumerousProprietary panels cited
    NoneNo FDA-cleared IEI test

    Coverage and Reimbursement Criteria

    Not reimbursable services

    The policy states the following are not reimbursable due to lack of evidence:

    IEI diagnostic testing: In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) are not reimbursable.
    Toxin/chemical profiling: In all circumstances, screening of blood, saliva, serum, plasma, urine, and/or stool samples for volatile solvents, organic acids, and organophosphates is not reimbursable.
    Phthalates and parabens profiling: In all circumstances, profiling of phthalates and parabens using blood, serum, plasma, saliva, urine, and/or stool samples is not reimbursable.
    Chlorinated pesticides profiling in asymptomatic individuals:
    Policy Summary
    PayerPremera Bluecross
    PolicyDiagnosis of Idiopathic Environmental Intolerance (IEI) testing
    Policy CodePolicy G2056
    Change TypeAdded non-reimbursable statementcoding removal
    Effective DateFeb 6, 2026
    Last ReviewFeb 6, 2026
    Next Review Date
    Key ActionDo not order tests intended to diagnose IEI — claims for any IEI testing will not be reimbursed.
    SourceLink
    On This Page
    Coverage and Reimbursement CriteriaWhen Testing May Be ConsideredCoding and Procedure CodesProvider Requirements, Documentation, and Billing ImpactAppropriate Ordering and DocumentationSpecific Tests and Panels Not CoveredPolicy Background and Evidence SummaryKey DefinitionsPolicy Revisions
    For asymptomatic individuals, profiling of chlorinated pesticides, including DDE and DDT, using blood, serum, plasma, saliva, urine, and/or stool samples is not reimbursable.
    Nutritional/metabolic testing for asymptomatic/general encounter: In asymptomatic individuals and/or during general encounters without abnormal findings, testing of blood, serum, plasma, saliva, urine, and/or stool samples for carnitine sufficiency, oxidative stress and antioxidant sufficiency, detoxification adequacy, methylation status, lipoic acid and CoQ10 sufficiency, and/or intestinal hyperpermeability is not reimbursable.
    Vitamin/mineral and nutritional analysis in asymptomatic/general encounter: In asymptomatic individuals and/or during general encounters without abnormal findings, testing of blood, serum, plasma, saliva, urine, and/or stool samples for vitamin sufficiency, mineral sufficiency, and/or nutritional analysis is not reimbursable.
    Breath hydrogen/methane tests for listed indications: The use of a breath hydrogen and/or breath methane test to assess or diagnose idiopathic environmental intolerance (IEI) and other listed conditions (eg, food allergies/sensitivities, carbohydrate intolerance, digestive disorders, constipation/diarrhea/flatulence, neurological/neuromuscular disorders, rosacea, obesity, or as part of a wellness visit without abnormal findings) is not reimbursable.
    Metals testing in asymptomatic/general encounter: In asymptomatic individuals and/or during general encounters without abnormal findings, testing for metals on blood, serum, urine, cerebrospinal fluid, fingernails, hair, and/or stool samples is not reimbursable.

    Not Medically Necessary / Not Reimbursable for IEI testing

    Not covered when the following applies

    IEI testing not reimbursable: All testing performed to diagnose idiopathic environmental intolerance (IEI) is not reimbursable.

    Explicit policy statement added to Routine Test Management; no clinical exceptions listed in this extract.

    The policy explicitly lists a broad set of specimen types and analytes that are not reimbursable when used to diagnose idiopathic environmental intolerance (IEI). Specimens called out include blood, serum, plasma, saliva, urine, stool, cerebrospinal fluid, fingernails, hair and related matrices. Analytes and profiles described as excluded include screening or profiling for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (including DDE and DDT), and testing for metals on the specimen types noted above.

    The policy cites professional society guidance that recommends against routine use of nonvalidated tests for IEI. Examples referenced include position statements and reviews from the American Medical Association (AMA), American Academy of Allergy, Asthma, and Immunology (AAAAI), American College of Occupational and Environmental Medicine (ACOEM), and the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), which advise avoiding unproven laboratory panels and emphasize psychological or clinical assessment rather than nonvalidated specialty testing.

    An explicit insertion into the Routine Test Management section states: In all circumstances, any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable. This policy-level statement applies universally and should be used to guide coverage decisions and claim adjudication.

    Testing intended to confirm a diagnosis of IEI is described as not reimbursable because the policy finds a lack of available published scientific literature demonstrating that such tests are required or beneficial for diagnosis or treatment. The policy therefore treats laboratory testing to establish IEI as not medically necessary.

    The policy notes that hepatic proteins (eg, albumin, prealbumin) and intracellular micronutrient panels are not appropriate as standalone diagnostic tools. It references consensus guidance that serum hepatic proteins are not reliable indicators of nutritional status alone, and concludes intracellular micronutrient analyses have little evidence showing they improve health outcomes; therefore these tests should not be used in isolation to diagnose malnutrition or IEI.

    Consistent with the Routine Test Management addition, the policy designates testing to diagnose IEI as not reimbursable. The language is unqualified in the extract: all claims for testing performed to diagnose idiopathic environmental intolerance are subject to denial under this policy.

    When Testing May Be Considered

    Symptom-guided testing for specific clinical conditions

    Covered when ALL of the following are met:

    Initial clinical evaluation: Evaluation includes a detailed history, physical examination, and baseline laboratory tests (complete blood count, serum electrolytes, glucose, urinalysis).

    Document occupational/environmental exposures and consider psychiatric screening (eg, PHQ-9) as recommended.

    Symptom-guided further testing: Further diagnostic testing must be guided by the patient’s reported symptoms rather than broad proprietary panels or indiscriminate screening.

    Avoid routine use of nonvalidated tests for IEI; targeted testing per clinical presentation only.

    Symptomatic patients with compatible GI symptoms and predisposing conditions — Breath testing for SIBO

    Breath testing for SIBO or carbohydrate maldigestion may be considered when ALL of the following are met:

    Compatible symptoms: Patient has compatible gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, excessive gas or flatulence.
    Other diagnoses excluded: An alternative diagnosis has been reasonably excluded by prior evaluation (eg, imaging, endoscopy) where indicated.
    Predisposing conditions present: There are underlying conditions that predispose to SIBO (eg, prior luminal abdominal surgery, suspected motility disorder, or other recognized risk factors).

    Document prior surgeries or conditions that increase SIBO risk.

    Appropriate test selection and documentation: Breath testing (glucose or lactulose hydrogen/methane) is selected based on clinical question and guidelines; documentation must include symptoms, prior evaluation, and clinical rationale.

    Consider methane testing when constipation predominates; perform lactose/fructose breath tests for at least 3 hours per guideline recommendations.

    Prior step: rule out bacterial overgrowth before carbohydrate breath testing: Presence of bacterial overgrowth should be considered prior to performing lactose or fructose breath testing, per expert guidance.

    Breath testing may assess antibiotic-responsive microbial colonization when culture is not feasible.

    Coding and Procedure Codes

    Listed CPT/HCPCS codes referenced in policymixed
    82108Aluminum
    82127Amino acids; single, qualitative, each specimen
    82136Amino acids, 2 to 5 amino acids, quantitative, each specimen
    82139Amino acids, 6 or more amino acids, quantitative, each specimen
    82300Cadmium
    82379Carnitine (total and free), quantitative, each specimen
    82380Carotene
    82441Chlorinated hydrocarbons, screen
    82495Chromium
    82507Citrate
    1–10 of 39
    1/4
    Removed CPT CodesCPT
    83921CPT code removed
    84600CPT code removed
    inv-11: Lactose dose for hydrogen breath test (adults)
    Recommended adult lactose dose25–50 g lactose for individuals aged 18 years and older
    Pediatric dosing noteNo consensus for children; estimates range 0.5–2 g/kg up to a maximum of 25–50 g
    Pre-test preparationAvoid complex carbohydrates and dairy for 12 hours; avoid smoking or strenuous activity for 2 hours
    Medication withholdingAvoid antibiotics for 4 weeks and colonic cleansing procedures for at least 2 weeks prior to testing
    Suggested test durationSuggested testing time is 3–5 hours; standard measuring interval for malabsorption is 30 minutes (longer intervals up to 60 minutes may be appropriate)

    Provider Requirements, Documentation, and Billing Impact

    Prior Authorization

    Prior authorization / coverage note — breath tests for IEI

    Breath hydrogen and/or methane testing (CPT 91065) is included in the coding list but the policy explicitly states that use of a breath hydrogen and/or breath methane test to assess or diagnose idiopathic environmental intolerance (IEI) is not reimbursable.

    • CPT 91065 is listed in the coding section but excluded when used to assess or diagnose IEI.
    • Providers should confirm member benefits for any breath testing unrelated to IEI indications.
    Prior Authorization

    Prior authorization — laboratory‑developed tests (LDTs)

    Laboratory-developed tests (LDTs) for IEI are performed in-house and are regulated under CLIA as high-complexity tests; the policy notes these tests are generally not FDA-cleared and may be subject to payer-specific prior authorization.

    • LDTs are regulated by CMS as high-complexity tests under CLIA '88.
    • LDTs are not approved or cleared by the FDA; clinical use does not require FDA clearance but coverage may be affected.
    Billing Rule

    Coding update — removed CPT codes (prior auth impact not specified)

    The policy documents a coding update removing CPT codes 83921 and 84600; no specific changes to prior authorization rules are specified in the extract.

    • Removed CPT codes: 83921 and 84600 (coding update noted 02/06/26).
    • No explicit prior authorization impacts described in the policy extract.
    Step Therapy

    Clinical step approach — prioritize history, exam, and targeted testing

    Before ordering broad proprietary panels for IEI, providers should prioritize a focused clinical evaluation — history, physical exam, baseline labs — and reserve targeted testing guided by symptoms rather than ordering broad, nonvalidated panels.

    • Initial evaluation should include history, physical examination, and baseline laboratory tests (CBC, serum electrolytes, glucose, urinalysis).
    • Further testing should be symptom-guided; avoid broad proprietary panels to evaluate IEI.
    Step Therapy

    Preferred diagnostic sequence for SIBO — breath testing first

    For suspected SIBO, guidelines recommend using noninvasive breath testing (glucose or lactulose hydrogen breath tests) to assess antibiotic‑responsive microbial colonization and to evaluate methane production in patients with constipation prior to more invasive testing.

    • Breath testing is suggested to assess antibiotic‑responsive microbial colonization and to evaluate excessive methane excretion in association with constipation.
    • Consider breath testing (glucose or lactulose) before invasive small bowel culture techniques which are not a satisfactory routine standard.
    Note

    Reserved

    Reserved.

    Documentation Required

    Recommended clinical evaluation documentation — history, exam, baseline labs

    When evaluating suspected IEI, document a detailed history and physical exam and include baseline laboratory tests: complete blood count (CBC), serum electrolytes, glucose, and urinalysis as part of the initial assessment.

    • Include occupational/environmental exposure history and consider psychiatric screening (eg, PHQ-9) as recommended.
    • Use baseline labs (CBC, electrolytes, glucose, urinalysis) to guide further, symptom-directed testing.
    Documentation Required

    Documentation for breath testing — record symptoms, prior evaluations, rationale

    When ordering breath testing (eg, for SIBO or carbohydrate maldigestion), document the patient's clinical symptoms, prior evaluations (imaging/endoscopy), clinical rationale for testing, and any prior surgeries or conditions that predispose to SIBO.

    • Document symptoms such as bloating, abdominal pain, diarrhea, gas and note prior luminal abdominal surgery or suspected motility disorders.
    • Record rationale for breath testing and prior evaluations to support the indication for testing.
    Documentation Required

    Documentation note — IEI testing not reimbursable; verify member benefits

    The policy has been added to Routine Test Management clarifying that testing for idiopathic environmental intolerance (IEI) is not reimbursable; providers should consult the member benefit booklet or customer service for member‑specific coverage details before ordering.

    • Explicit policy statement: In all circumstances, any type of testing for IEI is not reimbursable.
    • Check member benefit booklet or contact member services to determine coverage for related services.
    Denial Risk

    Denial risk — diagnostic testing for IEI not reimbursable

    Ordering laboratory tests intended to confirm a diagnosis of idiopathic environmental intolerance (IEI) will not be reimbursed; providers risk denial of claims for such testing.

    • The policy states: In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance is not reimbursable.
    • Do not submit claims for tests ordered solely to diagnose IEI.
    Denial Risk

    Denial risk — toxin/chemical/metal profiling not reimbursable

    Screening or profiling panels for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides, and metals using blood, serum, plasma, saliva, urine, stool, fingernails, or hair are not reimbursable and will be denied.

    • Policy items explicitly exclude these analytes and specimen types from reimbursement when used for IEI or in asymptomatic individuals.
    • Avoid ordering these profiling tests for the purpose of diagnosing IEI.
    Note

    LDT regulatory note — CLIA high‑complexity; generally not FDA‑cleared

    Laboratory‑developed tests (LDTs) used to evaluate IEI are CLIA‑regulated as high‑complexity tests and are generally not FDA‑cleared; lack of FDA clearance is noted in the policy and may influence coverage decisions.

    • LDTs must be validated and are regulated under CLIA '88 as high‑complexity tests.
    • The policy states no specific FDA‑cleared test for IEI was found; LDTs are not FDA‑approved or cleared.
    Denial Risk

    Denial risk — all IEI testing excluded from reimbursement

    The policy includes an explicit addition: in all circumstances, any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable—claims for IEI testing will be denied.

    • This is an explicit Routine Test Management policy statement added to the document.
    • No clinical exceptions for IEI testing are listed in the extract.

    Appropriate Ordering and Documentation

    Note

    Ordering requirements: start with clinical evaluation and symptom‑driven targeted testing

    Appropriate ordering begins with a clinical evaluation (history, physical exam) and baseline labs; testing should be symptom‑driven and targeted rather than broad panel screening.

    • Perform psychiatric screening and obtain occupational/environmental exposure history before extensive laboratory testing.
    Documentation Required

    Ordering requirements: document symptoms and prior evaluations; limit breath testing to guideline‑supported symptomatic patients

    When ordering breath tests, document the patient’s clinical symptoms and prior evaluations (imaging/endoscopy) and order breath testing only for symptomatic patients where guidelines support its use (eg, suspected motility disorder, prior surgery, or constipation with suspected methane production).

    • Guidelines recommend breath testing in symptomatic patients and to evaluate methane in association with constipation.
    • Ensure documentation explains how the test result will influence management.

    Specific Tests and Panels Not Covered

    Proprietary multi-analyte panels and commercial ‘profiling’ tests commonly marketed for IEI (examples named in the policy include panels from Genova Diagnostics (Organix, NutrEval, Triad Bloodspot, GI Effects, SIBO Profile), SpectraCell (Micronutrient Test, SPECTROX), Vibrant, and Life Extension) are specifically cited as not reimbursable when used to diagnose or manage IEI. The policy treats these proprietary panels as covered by the non-reimbursable exclusions.

    The policy states there is insufficient evidence to recommend breath testing for many carbohydrate substrates. For sugars such as fructose, sorbitol, trehalose, maltitol, and sucrose, the literature lacks validation and a gold standard, and therefore breath tests for these substrates are considered unsupported and not recommended for routine clinical use.

    The policy explicitly declares that all testing for idiopathic environmental intolerance (IEI) is not reimbursable. This blanket statement appears in the Routine Test Management addition and is reiterated in the coverage criteria as the primary coverage stance, with no clinical exceptions provided in the cited extract.

    Policy Background and Evidence Summary

    Background context describes idiopathic environmental intolerance (IEI), formerly multiple chemical sensitivity, as a subjective condition characterized by recurrent, nonspecific symptoms attributed to low-level environmental exposures in the absence of consistent objective physical findings or laboratory markers. The policy notes symptom heterogeneity and overlap with other disorders and states there are no reliable laboratory findings that consistently diagnose IEI.

    Key Definitions

    inv-26: Definition — Idiopathic environmental intolerance (IEI)
    DefinitionIdiopathic environmental intolerance (IEI) is a subjective condition with recurrent, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents in the absence of consistent objective diagnostic physical findings or laboratory tests.
    Former termAlso known as multiple chemical sensitivity (MCS).
    Typical featuresPatients report sensitivity to multiple, chemically unrelated substances and heterogeneous nonspecific symptoms such as anxiety, shortness of breath, and chest pain.
    inv-27: Definition — SIBO (small intestinal bacterial overgrowth) — breath testing context
    SIBO in breath-testing contextSIBO may be assessed by breath testing that measures hydrogen and/or methane after administration of a carbohydrate substrate (eg, lactulose or glucose); an early rise in breath gases suggests small bowel bacterial metabolism.
    Substrates usedCommon substrates include lactulose and glucose; choice affects test performance and interpretation.
    LimitationsBreath tests have limitations including variable sensitivity/specificity, potential false-positives from rapid transit, and false-negatives with delayed gastric emptying; correlation with small bowel aspiration culture is poor.
    inv-28: Definition — Small Intestinal Bacterial Overgrowth (SIBO) clinical description
    Clinical descriptionSmall intestinal bacterial overgrowth (SIBO) is a condition in which excessive aerobic and anaerobic bacteria colonize the small intestine and can cause chronic diarrhea and malabsorption.
    SymptomsMay present with chronic diarrhea, bloating, abdominal pain, gas, and features of malabsorption.
    Diagnostic approachesCan be assessed by noninvasive breath tests or by small bowel aspiration and culture, but no universally accepted gold standard exists.
    inv-29: Definition — Laboratory-Developed Test (LDT) regulatory note
    What an LDT isA laboratory-developed test (LDT) is a diagnostic test developed and performed in-house by a laboratory.
    Regulatory oversightLDTs are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under CLIA '88.
    FDA statusLDTs are generally not approved or cleared by the U.S. Food and Drug Administration; FDA clearance is not currently required for clinical use.
    inv-30: Definition — IEI / Multiple Chemical Sensitivity referenced in literature and consensus
    Literature contextIEI / MCS is referenced across multiple clinical and consensus publications, including AAAAI and ACOEM position statements and contemporary reviews.
    Clinical characterizationDescribed as self-reported sensitivity to environmental exposures with heterogeneous, nonspecific symptoms and without consistent objective diagnostic findings.
    Professional guidanceSeveral professional organizations and reviews recommend against routine use of nonvalidated tests for IEI and note psychiatric assessment may be appropriate.

    Policy Revisions

    2025-11-01policy_created

    New policy approved October 14, 2025 and published as a Routine Test Management policy stating that in all circumstances any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable; effective for dates of service on or after 2026-02-06 following 90-day provider notification.

    2026-02-06coding_updateLatest

    Coding update removing CPT codes 83921 and 84600 from the policy coding list.